Chris Wai Hang Lo

Chris Wai Hang Lo

Auto-generated profile, based on publicly available information

Chris Wai Hang Lo

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
CLChris Wai Hang Lo
Chris Wai Hang Lo
SPSwathi Pathadka
Swathi Pathadka
SQSimon Xiwen Qin
Simon Xiwen Qin
LFLydia W.Y. Fung
Lydia W.Y. Fung
VYVincent Ka Chun Yan
Vincent Ka Chun Yan
ECEsther W Chan
Esther W Chan
Background: The United States Food and Drug Administration issued a black box warning on the mental health adverse effects of montelukast in 2020. Age-related effects on the risk of developing specific neuropsychiatric events in montelukast users remain largely unknown.Objective: To describe the risk of neuropsychiatric events associated with montelukast in adults and children with asthma.Methods: A systematic search of all studies investigating neuropsychiatric events in montelukast users was performed in PubMed, the Cochrane Library and Embase from inception to 7 September 2022. Animal studies and conference abstracts were excluded.Results: 59 studies (21 pharmacovigilance studies, four reviews from 172 randomised controlled trials, 20 observational studies, 10 case reports and four case series) evaluating neuropsychiatric events in patients with asthma on montelukast were reviewed. No significant association was shown between montelukast and suicide-related events in six of the observational studies. No association was found for depression as defined by the International Classification of Diseases 10threvision codes in three observational studies and a review of randomised clinical trials. However, findings from four studies using antidepressant prescriptions as the outcome identified significant associations. Consistent with nine pharmacovigilance studies, two large-scale observational studies revealed possible associations of montelukast with anxiety and sleeping disorders in adult patients with asthma, respectively. However, the results were not replicated in two observational studies on children.Conclusion: Montelukast is not associated with suicide- and depression-related events in asthma patients. Older adults may be particularly susceptible to anxiety and sleeping disorders.

10 April 2025 in Biological Psychiatry Global Open Science
Verified
Journal Article
Open access
CLChris Wai Hang Lo
Chris Wai Hang Lo
AGAlexandra C. Gillett
Alexandra C. Gillett
MIMatthew H. Iveson
Matthew H. Iveson
MKMichelle Kamp
Michelle Kamp
CFChiara Fabbri
Chiara Fabbri
CLCathryn Lewis
Cathryn Lewis
Selective serotonin reuptake inhibitors (SSRIs) are a first-line pharmacological therapy in major depressive disorder (MDD), but treatment response rates are low. Clinical trials lack the power to study the genetic contribution to SSRI response. Real-world evidence from electronic health records provides larger sample sizes, but novel response definitions are needed to accurately define SSRI nonresponders. In the UK Biobank (UKB) (N = 38,813) and Generation Scotland (N = 1777) datasets, SSRI switching was defined using ≤90-day gap between prescriptions for an SSRI and another antidepressant in primary care. Nonswitchers were participants with ≥3 consecutive prescriptions for an SSRI. In the UKB, clinical, demographic, and polygenic score (PGS) associations with switching were determined, and the common-variant heritability was estimated. In the UKB, 5133 (13.2%) SSRI switchers and 33,680 nonswitchers were defined. The mean time to switch was 28 days (interquartile range, 17–49). Switching patterns were consistent across the UKB and Generation Scotland (n = 498 switchers). Higher annual income and educational levels (odds ratio [OR] [95% CI] for a university degree, 0.73 [0.67–0.79] compared with no qualifications) were associated with lower levels of switching. PGSs for nonremission, based on clinical studies, were associated with increased risk of switching (OR, 1.07 [1.02–1.12], p = .007). MDD PGSs and family history of depression were not significantly associated with switching. Using genome-wide complex trait Bayesian, the single nucleotide polymorphism–based heritability was approximately 4% (SE 0.016) on the observed scale. This study identified SSRI switching as a proxy for nonresponse, scalable across biobanks with electronic health records, capturing demographics and genetics of treatment nonresponse, and independent of MDD genetics.

5 March 2021 in Cardiac Failure Review
Verified
Journal Article
Open access
CLChris Wai Hang Lo
Chris Wai Hang Lo
YFYue Fei
Yue Fei
BCBernard MY CHEUNG
Bernard MY CHEUNG
Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk.

12 March 2025 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
MKMichelle Kamp
Michelle Kamp
CLChris Wai Hang Lo
Chris Wai Hang Lo
GKGrigorios Kokkinidis
Grigorios Kokkinidis
MCMimansa Chauhan
Mimansa Chauhan
AGAlexandra C. Gillett
Alexandra C. Gillett
CLCathryn Lewis
Cathryn Lewis
Background: In major depressive disorder (MDD), only ~35% achieve remission after first-line antidepressant therapy. Using UK Biobank data, we identify sociodemographic, clinical, and genetic predictors of antidepressant response through self-reported outcomes, aiming to inform personalized treatment strategies. Methods: In UK Biobank Mental Health Questionnaire 2, participants with MDD reported whether specific antidepressants helped them. We tested whether retrospective lifetime response to four selective serotonin reuptake inhibitors (SSRIs) (N = 19,516) – citalopram (N = 8335), fluoxetine (N = 8476), paroxetine (N = 2297) and sertraline (N = 5883) – was associated with sociodemographic (e.g. age, gender) and clinical factors (e.g. episode duration). Genetic analyses evaluated the association between CYP2C19 variation and self-reported response, while polygenic score (PGS) analysis assessed whether genetic predisposition to psychiatric disorders and antidepressant response predicted self-reported SSRI outcomes. Results: 71%–77% of participants reported positive responses to SSRIs. Non-response was significantly associated with alcohol and illicit drug use (OR = 1.59, p = 2.23 × 10−20), male gender (OR = 1.25, p = 8.29 × 10−08), and lower-income (OR = 1.35, p = 4.22 × 10−07). The worst episode lasting over 2 years (OR = 1.93, p = 3.87 × 10−16) and no mood improvement from positive events (OR = 1.35, p = 2.37 × 10−07) were also associated with non-response. CYP2C19 poor metabolizers had nominally higher non-response rates (OR = 1.31, p = 1.77 × 10−02). Higher PGS for depression (OR = 1.08, p = 3.37 × 10−05) predicted negative SSRI outcomes after multiple testing corrections. Conclusions: Self-reported antidepressant response in the UK Biobank is influenced by sociodemographic, clinical, and genetic factors, mirroring clinical response measures. While positive outcomes are more frequent than remission reported in clinical trials, these self-reports replicate known treatment associations, suggesting they capture meaningful aspects of antidepressant effectiveness from the patient’s perspective.

14 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DLDanyang Li
Danyang Li
CLChris Wai Hang Lo
Chris Wai Hang Lo
CLCathryn Lewis
Cathryn Lewis
EVEvangelos Vassos
Evangelos Vassos
GBGerome Breen
Gerome Breen
Background: Antidepressants are the most prescribed medications in psychiatry. Medical records provide a valuable opportunity to explore prescribing patterns and to uncover clinical and genetic factors that influence treatment outcomes. Methods: Using longitudinal primary care records from the UK Biobank, we investigated antidepressant change patterns in both depression and non-depression indications. We examined outcomes including the number of antidepressant changes, and discontinuation that is likely due to intolerable side effects or inadequate response. Genetic analyses including heritability estimation, genetic correlation and polygenic score association were performed. Results: A total of 82,633 individuals in the UK Biobank were prescribed at least one of 37 antidepressants. Of these, 28,332 had a depression diagnosis and 24,543 did not. Selective serotonin reuptake inhibitors (SSRIs), including citalopram and fluoxetine, were the most prescribed antidepressants for depression, while tricyclic antidepressants, especially amitriptyline, dominated prescriptions in non-depression indications. Individuals with depression were more likely to stay on antidepressants longer than those without depression, and to follow preferred antidepressant choices that have changed over time. For depression, discontinuation rates for SSRIs were 9% for likely intolerable side effects and 12% for likely nonresponse. Antidepressant change and discontinuation were significantly enriched for psychiatric and somatic conditions, including recurrent depression, anxiety in the depression group, and pain-related conditions in the non-depression group. Genetic analyses identified two novel variants associated with SSRI early discontinuation. Notable genetic overlap was shown between these antidepressant phenotypes and multiple psychiatric and physical traits, and polygenic scores had significant prediction for treatment outcomes. Conclusions: These findings provide a valuable framework for characterising antidepressant change in primary care records and highlight the potential of integrating clinical and genetic data to better understand factors influencing treatment outcomes. Replication in other large-scale medical records will be essential to advance the discovery of genetic variants associated with antidepressant outcomes.

8 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CLChris Wai Hang Lo
Chris Wai Hang Lo
DHDale Kevin Michael Handley
Dale Kevin Michael Handley
OPOliver Pain
Oliver Pain
MKMichelle Kamp
Michelle Kamp
AGAlexandra C. Gillett
Alexandra C. Gillett
CLCathryn Lewis
Cathryn Lewis
Linkage between population-wide biobanks and electronic health records (EHRs) opens new opportunities to study the genetic and epidemiological underpinnings of treatment outcomes, a key step forward in delivering precision medicine. However, challenges include complexities in data extraction for longitudinal analyses, and the absence of reproducible phenotyping algorithms. Here, we present T-Rx, an open-source R package to streamline the processing of prescription and dispensing records, to enable reproducible and scalable analysis across EHR databases. T-Rx consists of three modules to derive treatment-related phenotypes from uncleaned prescription records: (1) Extraction and Imputation Module for extracting and imputing prescription details; (2) Exposure Ascertainment Module for converting prescriptions to longitudinal exposure periods; and (3) Phenotyping Module for creating reproducible proxy phenotypes that capture treatment and response patterns. We tested the utility of T-Rx in UK Biobank primary care records, with strength and quantity information extracted and imputed for 2,721,921 antidepressant and 430,705 antipsychotic prescriptions. The extraction functions were validated using oral hypoglycemic agent prescriptions in Clinical Practice Research Datalink Aurum, showing comparable performances to extraction using the NHS Dictionary of Medicines and Devices (dm+d) codes. The Exposure Ascertainment Module of T-Rx converts discrete prescription or dispensing events into longitudinal exposure periods in one-line R commands, with customizable parameters to account for real-world treatment complexities. The Phenotyping Module takes prescriptions as direct user input and returns analysis -ready data frames. Current phenotyping algorithms include antidepressant switching and treatment-resistant depression. The phenotyping functions also allow flexible parameter choices, such as treatment episode windows, definitions for switching and quality control criteria. Researchers can contribute phenotyping algorithms to T-Rx for reproducible use. T-Rx improves the accessibility of prescription information in biobanks, and analysis of dosage- and treatment-patterns across therapeutic areas. T-Rx contributes to open science through harmonized phenotypic definitions and reproducible analyses of proxy treatment outcomes.